We Claim:

1. A method for treating a disorder remedied by antagonism of mGlu5 receptors in a patient which comprises administering to a patient in need thereof an effective amount of a compound of formula 1:



(1)

wherein

Ar is phenyl or napthyl each of which may be substituted by one or more C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_5 acyl, halo, amino, nitro, cyano, hydroxy, C_1-C_5 acylamino, C_1-C_4 alkylsulfonylamino, mono-, di- or trifluorinated C_1-C_3 alkyl, substituents which may be the same or different and may bear a $CONH_2$, $CONHCH_3$, $CON(CH_3)_2$, CO_2H, CO_2CH_3, OCF_3, $CH_2NHCOCH_3$, CH_2NH_2, $CH_2N(CH_3)_2$, CH_2CN, CH_2OH, $CH_2NHSO_2CH_3$, $CH_2N(CH_3)(CH_2)_2$ CN, $CH_2N(CH_3)CH(CH_3)_2$, $CH_2NHCH(CH_3)_2$, $CH_2NH(CH_2)_2CH_3$, $CH_2NHCO_2R^4$, $CH_2NHCH_2CH_3$, CH_2NHCH_3, $NHCOC(CH_3)_2$, or $N(S(O)_2CH_3)_2$ substituent;

R^1 is hydrogen, halo, R^4, CN, $C(NOH)R^3$, $C(NO\text{-}R^4)R^3$, $(CH)_2CO_2R^4$, $(CH_2)_n OR^3$, COR^3, CF_3, SR^4, $S(O)R^4$, $S(O)_2R^4$, $COCH_2CO_2R^3$, $NHSO_2R^4$, $NHCOR^3$, $C(NOR^3)NH_2$, CH_2OCOR^3, $(CH_2)_n NH_2$, $CON(CH_3)_2$, $(CH_2)_nNHCO_2R^4$, CO_2R^3, $CONH_2$, $CSNH_2$, $C(NH)NHOR^3$, $(CH_2)_nN(CH_3)_2$, or $CONHNHCOR^3$;

R^2 is 1,2-ethenediyl or 1,2-ethynediyl;

R^3 is hydrogen or C_1-C_4 alkyl;

R^4 is C_1-C_4 alkyl; and

n is 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof; or an N-oxide thereof.

2. A method as claimed in Claim 1 wherein

Ar is C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_5acyl, halo, amino, nitro, cyano, hydroxy, C_1-C_5 acylamino, C_1-C_4 alkylsulfonylamino or mono-, di- or trifluorinated C_1-C_3 alkyl; and

R^1 is hydrogen, halo, R^4, CN, $C(NOH)R^3$, $C(NOR^4)R^3$, $(CH)_2CO_2$-R^4, OR^3, COR^3 or CF_3.

3. The method of any one of Claims 1 or 2 wherein the disorder is pain or anxiety.

4. The method of any one of Claims 1-3 wherein the patient is a human.

5. A compound of formula 1:



(1)

wherein

Ar is phenyl or napthyl each of which may be substituted by one or more C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_5 acyl, halo, amino, nitro, cyano, hydroxy, C_1-C_5 acylamino, C_1-C_4 alkylsulfonylamino, mono-, di- or trifluorinated C_1-C_3 alkyl, substituents which may be the same or different and may bear a $CONH_2$, $CONHCH_3$, $CON(CH_3)_2$, CO_2H, CO_2CH_3, OCF_3, $CH_2NHCOCH_3$, CH_2NH_2, $CH_2N(CH_3)_2$, CH_2CN, CH_2OH, $CH_2NHSO_2CH_3$, $CH_2N(CH_3)(CH_2)_2$ CN, $CH_2N(CH_3)CH(CH_3)_2$, $CH_2NHCH(CH_3)_2$, $CH_2NH(CH_2)_2CH_3$, $CH_2NHCO_2R^4$, $CH_2NHCH_2CH_3$, CH_2NHCH_3, $NHCOC(CH_3)_2$, or $N(S(O)_2CH_3)_2$ substituent;

R^1 is hydrogen, halo, R^4, CN, $C(NOH)R^3$, $C(NO\text{-}R^4)R^3$, $(CH)_2CO_2R^4$, $(CH_2)_n$ OR^3, COR^3, CF_3, SR^4, $S(O)R^4$, $S(O)_2R^4$, $COCH_2CO_2R^3$, $NHSO_2R^4$, $NHCOR^3$,

$C(NOR^3)NH_2$, CH_2OCOR^3, $(CH_2)_n NH_2$, $CON(CH_3)_2$, $(CH_2)_nNHCO_2R^4$, CO_2R^3, $CONH_2$, $CSNH_2$, $C(NH)NHOR^3$, $(CH_2)_nN(CH_3)_2$, or $CONHNHCOR^3$;

R^2 is 1,2-ethenediyl or 1,2-ethynediyl;

R^3 is hydrogen or C_1-C_4 alkyl;

R^4 is C_1-C_4 alkyl; and

n is 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof; or an N-oxide thereof; provided that the compound is other than 5-phenylethynyl-nictinonitrile.

6. The compound of Claim 5 wherein n is 0 or 1.

7. The compound of any one of Claims 5 or 6 wherein Ar is phenyl substituted by one or more halo, C_1-C_4 alkyl, CN, C_1-C_4 alkoxy, CF_3, NO_2, NH_2, OH, $COCH_3$, substituents which may be the same or different and may bear a $CONH_2$, $CONHCH_3$, $CON(CH_3)_2$, CO_2H, CO_2CH_3, OCF_3, $CH_2NHCOCH_3$, CH_2NH_2, $CH_2N(CH_3)_2$, CH_2CN, CH_2OH, $CH_2NHSO_2CH_3$, $CH_2N(CH_3)(CH_2)_2$ CN, $CH_2N(CH_3)CH(CH_3)_2$, $CH_2NHCH(CH_3)_2$, $CH_2NH(CH_2)_2CH_3$, $CH_2NHCO_2C(CH_3)_3$, $CH_2NHCH_2CH_3$, CH_2NHCH_3 or $NHCOC(CH_3)_2$ substituent.

8. The compound of any one of Claims 5-7 wherein halo is fluoro, iodo, choro or bromo; alkyl is methyl, ethyl, propyl, isopropyl or isobutyl; and alkoxy is methoxy.

9. The compound of any one of Claims 5-8 wherein Ar is 2-chlorophenyl, 3-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3,4,5-trifluorophenyl, 3-bromophenyl, 3-nitrophenyl, 3-trifluoromethylphenyl, 3-aminophenyl,

3-chloro-4-fluorophenyl, 3-hydroxyphenyl, 3-acetylphenyl, 5-chloro-2-methoxyphenyl, 3-chloro-4-methoxyphenyl, 3-hydroxy-4-fluorophenyl, 3-methoxy-4-fluorophenyl, 3-ethoxy-4-fluorophenyl, 3-isopropoxy-4-fluorophenyl, 3-isopropylphenyl, 3-ethylphenyl, 3-methyl-4-fluorophenyl, 3-trifluoromethyl-4-fluorophenyl, 3-cyano-4-fluorophenyl, 3-amino-4-fluorophenyl, 3-trifluoromethyl-4-fluorophenyl, 3-chloro-4-fluorophenyl, 3-nitro-4-fluorophenyl, 3-aminocarbonyl-4-fluorophenyl, 3-N-methylaminocarbonyl-4-fluorophenyl, 3-N,N-dimethylaminocarbonyl-4-fluorophenyl, 3-carboxyl-4-fluorophenyl, 3-methoxycarbonyl-4-fluorophenyl, 3-acetylaminomethyl-4-fluorophenyl, 3-methysulfonylaminomethyl-4-fluorophenyl, 3-pivaloylaminomethyl-4-fluorophenyl, 3-trifluoromethoxyphenyl, 3-aminomethyl-4-fluorophenyl, 3-dimethylaminomethyl-4-fluorophenyl, 3-cyanomethyl-4-fluorophenyl, 4-fluoro-3-hydroxymethylphenyl, 3-{[(2-cyanoethyl)-methylamino]-methyl}-4-fluorophenyl, 4-fluoro-3-[(isopropylmethylamino)-methyl]phenyl, 4-fluoro-3-isopropylaminomethylphenyl, 4-fluoro-3-propylaminomethylphenyl, 3-ethylaminomethyl-4-fluorophenyl, 4-fluoro-3-methyl aminomethylphenyl, 3-isobutyrylamino-4-fluorophenyl or 3-aminophenyl.

10. The compound of any one of Claims 5-9 wherein R^1 is hydrogen, bromo, iodo, fluoro, chloro, $C(NOH)R^3$, $C(NO\text{-}R^4)R^3$, methyl, CN, $CH_2CO_2R^4$, $(CH_2)_nOR^3$, COR^3, CF_3, SR^4, $S(O)R^4$, $S(O)_2R^4$, $COCH_2CO_2R^3$, $NHS(O)_2R^3$, $NHCOR^3$, $CH_2OC(O)R^3$, $(CH^2)_nNH_2$, $CON(CH_3)_2$, $(CH_2)_nNHCO_2R^4$, CO_2R^3, $CONH_2$, $CSNH_2$, $C(NH)NHOR^3$, $(CH_2)_nN(CH_3)_2$ or $CONHNHCOR^3$.

11. The compound of any one of Claims 5-10 wherein R^3 is hydrogen, methyl, ethyl or *t*-butyl.

12. The compound of Claim 5 wherein

Ar is phenyl of napthyl each of which may be substituted by C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_5 acyl, halo, amino, nitro, cyano, hydroxy, C_1-C_5 acylamino, C_1-C_4 alkylsulfonylamino or mono-, di- or trifluorinated C_1-C_3 alkyl; and

R^1 is hydrogen, halo, R^4, CN, $C(NOH)R^3$, $C(NOR^4)R^3$ $(CH)_2CO_2R^4$, OR^3, COR^3 or CF_3.

13. The compound of formula I as claimed in any one of Claims 5-12 wherein R^1 is CN, iodo, chloro, methyl or COR^3.

14. The compound of formula I as claimed in any one of Claims 5-13 wherein R^1 is CN.

15. The compound of formula I as claimed in any one of Claims 5-14 wherein R^2 is 1,2-ethynediyl.

16. The compound of formula 1 as claimed in any one of Claims 5-15 wherein C_1-C_4 alkyl is methyl.

17. The compound of formula 1 as claimed in any one of Claims 5-16 wherein R^3 is methyl.

18. A compound of formula 1 as claimed in any one of a Claims 5-16 wherein R^3 is hydrogen.

19. The compound of any one of Claims 5-18 wherein substituted Ar is substituted phenyl.

20. The compound of any one of Claims 5-6, 8 or 10-18 wherein Ar is phenyl.

21. A compound of claim 5 which is:
5-(4-Fluorophenylethynyl)-nicotinonitrile, 5-(3-Cyanophenylethynyl)-nicotinonitrile or 5-(3,4-difluorophenylethynyl)-nicotinonitrile.

22. A process for preparing a compound of formula 1 (or a pharmaceutically acceptable salt thereof) as provided in any one of the above Claims 5-21 which comprises:

(a) for a compound of formula 1 in which R^2 is 1,2-ethenediyl, reacting with a compound of formula II



(II)

with a compound of formula Ar-$CHCH_2$ in a Heck coupling;

(b) for a compound of formula 1 in which R^2 is alkynyl, reacting with a compound of formula III



(III)

in a Sonogashira coupling with a compound of formula Ar-I or Ar-Br in a suitable solvent;

whereafter, for any of the above procedures, when a pharmaceutically acceptable salt of a compound of formula 1 is required, it is obtained by reacting the basic form of such a compound of formula 1 with an acid affording a physiologically acceptable

counterion, or, for a compound of formula 1 which bears an acidic moiety, reacting the acidic form of such a compound of formula 1 with a base which affords a pharmaceutically acceptable cation, or by any other conventional procedure; and wherein, unless more specifically described, the value of R^1, Ar and R^2 are as defined in Claim 5.

23. A pharmaceutical composition comprising in association with a pharmaceutically acceptable carrier, dilutent or excipient, a compound of formula 1 (or a pharmaceutically acceptable salt thereof) as provided in any one of the above Claims 5-21.

24. A compound of formula 1 as claimed in Claim 1 for use in therapy.

25. Use of compound of formula 1 as claimed in Claim 1 for the manufacture of a medicament for treating a disorder remedied by antagonism of mGlu5 receptors in a patient.